ZZPZH(SH:600436) Quan Jing Wang·2025-11-13 03:09Core Insights - The clinical trial for the new traditional Chinese medicine, Changjiaan Capsules, targeting Irritable Bowel Syndrome with Diarrhea (IBS-D), has officially commenced with a national researcher meeting held in Guangzhou [1][2] - The trial is approved by the National Medical Products Administration and is led by Beijing University of Chinese Medicine, involving 30 top-tier hospitals across the country [1][2] - The study is designed as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the clinical efficacy and safety of Changjiaan Capsules in alleviating core symptoms of IBS-D [1][2] Company Developments - The meeting was chaired by Professor Zhang Shengsheng, the principal investigator, who emphasized the importance of expert contributions to ensure the scientific and practical feasibility of the trial [2] - The project team presented preliminary research findings and key points of the Phase III trial design, including risk control strategies [2] - The meeting fostered extensive discussions on critical aspects such as inclusion/exclusion criteria, assessment indicators, and electronic reporting standards, leading to constructive feedback from experts [2] Future Outlook - The successful initiation of the Phase III clinical trial marks another innovative product from the company entering the confirmatory research phase [2] - The company plans to increase R&D investment, guided by the philosophy of "staying true to innovation and progressing steadily," to enhance the development of Changjiaan Capsules [2]